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Abstract
Background: The efficacy of artemisinin-based combination therapy has already been demonstrated in a number of studies all
over the world, and some of them can be regarded as comparably effective. Ease of administration of anti-malarial treatments
with shorter courses and fewer tablets may be key determinant of compliance.
Methods: Patients with uncomplicated falciparum malaria and over six months of age were recruited in Cameroon, Mali,
Rwanda and Sudan. 1,384 patients were randomly assigned to receive artesunate-sulphamethoxypyrazine-pyrimethamine (AS-
SMP) three-day (once daily for 3 days) regimen (N = 476) or AS-SMP 24-hour (0 h, 12 h, 24 h) regimen (N = 458) or artemether-
lumefantrine (AL), the regular 6 doses regimen (N = 450). The primary objective was to demonstrate non-inferiority (using a
margin of -6%) of AS-SMP 24 hours or AS-SMP three days versus AL on the PCR-corrected 28-day cure rate.
Results: The PCR corrected 28-day cure rate on the intention to treat (ITT) analysis population were: 96.0%(457/476) in the
AS-SMP three-day group, 93.7%(429/458) in the AS-SMP 24-hour group and 92.0%(414/450) in the AL group. Likewise, the cure
rates on the PP analysis population were high: 99.3%(432/437) in the AS-SMP three-day group, 99.5%(416/419) in the AS-SMP
24-hour group and 99.7(391/394)% in the AL group. Most common drug-related adverse events were gastrointestinal symptoms
(such as vomiting and diarrhea) which were slightly higher in the AS-SMP 24-hour group.
Conclusion: AS-SMP three days or AS-SMP 24 hours are safe, are as efficacious as AL, and are well tolerated.
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Background
Over the last few years artemisinin-based combination
therapy (ACT) is widely accepted as an appropriate treat-
ment for malaria. This disease remains an important
killer, particularly in childhood, in sub-Saharan Africa [1-
3]. ACT offers new therapeutic possibilities and the World
Health Organization (WHO) has recommended a series
of such combinations with several studies in progress [4].
The efficacy of ACT has already been demonstrated in a
number of studies all over the world [5-7], and some of
them can be regarded as comparably effective, when using
adequate clinical and parasitological responses as a meas-
ure of final outcome [8]. One of the conclusions of this
analysis states that secondary factors, such as side effects,
ease of administration, cost, duration of the treatment,
become important, when selecting the appropriate treat-
ment. Ease of administration of anti-malarial treatments
is a key determinant of compliance and, therefore, effi-
cacy, with shorter courses and fewer tablets being pre-
ferred over the current minimum of three days and
multiple tablets a day for most forms of ACT. These sec-
ondary factors must be considered when selecting an anti-
malarial treatment, since they can greatly influence the
final outcome. A fixed-dose artemisinin-based combina-
tion (FDC) treatment would be able to improve compli-
ance of the treatment and reduce the cost of malarial
treatment in endemic countries in Africa.
In a recent communication, WHO experts announced that
the ideal anti-malarial drug should have an efficacy of at
least 95% as measured over 28 days of follow-up. They
recommend that re-infection in that period should be
minimal and that, ideally, the treatment should be
restricted to a few pills administered as a single dose and
should have a short treatment duration [9]. To try and
improve the existing ACT, artesunate (AS) was combined
with sulphamethoxypyrazine-pyrimethamine (SMP) in a
co-blister. This combination of AS-SMP (Co-Arinate®),
taken once daily (two tablets simultaneously) over three
days, was studied in Mali [10], Ivory Coast (Dafra Pharma
file), Rwanda [11], and is available as a prescription drug
in numerous African countries. Based on this experience,
a fixed-dose combination (Co-Arinate FDC®), was subse-
quently developed. Since preliminary experiments with
these tablets indicated that the dosing interval could be
reduced to 12 hours enabling a 24-hour therapy [12,13],
it was of interest to evaluate in a larger population
whether this dosage regimen is equally effective compared
with the same treatment given over 48 hours (dose inter-
val of 24 hours). It was decided to use the WHO standard
essential drug Coartem® (AL FDC), available as a six-dose
regimen, as standard therapy for assessing AS-SMP FDC.
The primary objective was to demonstrate the non-inferi-
ority of AS-SMP 24 hours or AS-SMP three days versus AL
on the PCR-corrected 28-day cure rate.
Methods
Study sites
This multi-centre study, which took place in four African
countries: Cameroon, Mali, Rwanda and Sudan. In Cam-
eroon, the study took place in the capital city, Yaoundé.
The study site was the Cameroon Baptist Convention
clinic in the peri-urban district of Biyem-Assi. Transmis-
sion in Yaoundé occurs in two peak periods at the start of
the rainy season in March/April, and in October/Novem-
ber as the rains cease. Chloroquine resistance is above
45%, amodiaquine resistance is about 10% and resistance
to sulphadoxine/pyrimethamine (SP) is higher than 10%
in Yaoundé or other parts of Cameroon [14,15].
In Mali, the study took place at Bancoumana health center
and surrounding villages (Kolle and Samako). The study
area is located at about 60 km south-west of Bamako. The
main population activity is farming. Malaria is hyperen-
demic and the transmission is mainly seasonal from June
to December. Plasmodium falciparum is the predominant
plasmodium species, accounting for more than 95% of
malaria cases. Chloroquine resistance is above 25% [16,17]
and resistance to SP is around 5% in a part of this area.
In Rwanda, the study took place in Rwamagana and
Muhimai. The study area is located at about 50 km east of
Kigali. The main population activity is farming. Malaria is
hyperendemic. Plasmodium falciparum is the predominant
plasmodium species, accounting for more than 95% of
malaria cases. Resistance to SP exceeded 25% [18].
In Sudan the study took place at Alhara Alola health
center in New Hlafa, eastern Sudan. This area is located at
500 km from Khartoum in the middle of the second larg-
est irrigated agricultural scheme in Sudan. Cotton and
wheat are the main crops cultivated during the winter sea-
son. The area is characterized by a high level of P. falci-
parum resistance to chloroquine (>70%) and the reported
SP resistance in Sudan is ranging from 5% to 30% [19,20].
Patients
This study recruited patients presenting at the health
center with typical symptoms of malaria and who had a
blood smear positive for P. falciparum. Inclusion criteria
were: above six months of age, weight above5 kg, infec-
tion with P. falciparum (asexual stages 2,000–200,000/μL)
at screening, fever (axillary temperature ≥37.5°C or a his-
tory of fever in the preceding 24 hours), resident of study
site, able to take oral treatment. Exclusion criteria were:
symptoms or signs of severe malaria [21], serious under-
lying diseases or any other illness that required a treat-
ment non-compatible with the study, allergy to study
drugs, use of any component of the study drugs within the
last 28 days prior enrollment, and pregnancy (detected
clinically, or with beta human chorionic gonadotrophin
test (HCG)).Malaria Journal 2009, 8:63 http://www.malariajournal.com/content/8/1/63
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Study design
This was a prospective in vivo efficacy study. It was a ran-
domized open label trial comparing fixed dose AS-SMP
24-hour or three-day regimen to AL as the standard refer-
ence treatment. The laboratory personnel assessing the
parasitaemia was kept blinded. The study was carried out
according to current WHO 2003 Protocol [22].
Study procedures and treatment
Enrolled patients were randomly assigned a fixed dose of
AS-SMP (Co-Arinate FDC®, Dafra Pharma, Belgium), as a
24-hour or three-day regimen, or AL (Coartem®,
Novartis). The randomization code was computer-gener-
ated by a third party not involved in patients' outcome
assessment. It was a block randomization procedure strat-
ified by country. Study codes were sealed in individual
envelopes and securely stored. Randomized patients were
assigned a study number in numerical sequence by the
investigators. All drugs were manufactured according to
Good Manufacturing Practice (GMP). AL tablets were a
fixed combination, each containing 20 mg of artemether
and 120 mg of lumefantrine. AL was administrated
according to body weight (5–14 kg: one tablet; 15–24 kg:
two tablets; 25–34 kg: three tablets; ≥35 kg: four tablets)
as six consecutive doses: The first dose at diagnosis and
the second dose eight hours later on Day 0, and then two
doses at 12 hourly intervals for the subsequent two days.
AS-SMP FDC is available as adult, junior and baby treatment
packs. The adult tablet contains 200 mg artesunate, 500 mg
of sulphamethoxypyrazine and 25 mg of pyrimethamine,
while each junior tablet contains 100 mg of artesunate, 250
mg of sulphamethoxypyrazine and 12.5 mg of pyrimeth-
amine, and each baby tablet contains 50 mg of artesunate,
125 mg of sulphamethoxypyrazine and 6.25 mg of
pyrimethamine. The dosage for this study was determined by
weight, with adults weighing 40 – 79 kg and >79 kg receiving
one tablet and one and a half tablet of the adult preparation,
respectively. One tablet of junior preparation was given to
individuals weighing between 20 and 40 kg and the baby
preparation was given at a dose of one and a half tablets, one
tablet and a half tablet for children weighing between 13 and
20 kg; between eight and 13 kg, and between five and eight
kg, respectively.
Patients allocated to the three-day treatment with AS-SMP
FDC were given their treatment three times, at an interval
of 24 hours (0 h – 24 h – 48 h). Patients allocated to the
24-hour treatment with AS-SMP FDC were given tablets
for three consecutive intakes at an interval of 12 hours (0
h – 12 h – 24 h).
All study drug doses were administrated at the heath
center by the study team. A full drug dose was re-adminis-
trated if the patients either spat out or vomited the study
drugs within 30 minutes. Half the drug dose was re-
administrated if the patient vomited the study drugs
between 30 minutes to one hour. If the patient rejected
again, he/she received another anti-malarial drug in con-
formity with the National Malaria Control Programme of
his/her respective country, and was then excluded from
the study.
Follow-up examinations were made on days 0, 1, 2, 3, 7,
14, 21 and 28 or at any time if patient felt unwell. Blood
from a finger prick was obtained to make a thick smear
and a filter paper dot during each day of follow-up. The
patients or guardians were asked about drug consumption
since the last clinic visit. Individuals for whom treatment
failed were treated according to National Malaria Control
Programme. Giemsa-stained thick smears were read by an
experienced microscopist blinded to study arm. Parasitae-
mia was quantified by a standard approximation method
(40 × number of parasites per 200 leucocytes on the thick
film). Slide quality control was done by masked re-read-
ing of 10% of slides, selected randomly. Haematological
tests (Complete Blood Count) and biochemistry analyses
(concentrations of alanine aminotransferase, bilirubin
and creatinine) were done at baseline and at day 7 and
then on day 28. Patients at Cameroon site and few
patients at Sudan site did the blood test on day 14 instead
of day 7. The tests were done any time for any subject if
clinically recommended or in case of significant abnor-
mality in tests during scheduled lab visits. Venous whole
blood collected in anticoagulant tube was used for hae-
matological tests, while venous blood collected in serum
separator tube was used for biochemistry analyses. Less
than 10 ml of blood was needed for these tests.
For participants with recurrent parasitaemia after day 7,
paired polymerase chain reaction (PCR) blots (from day 0
and the day of parasitaemia recurrence) were analysed for
parasite merozoite surface protein 1 and 2 genes (msp1
and  msp2) and microsatellite (CA1), to distinguish
between re-infection and recrudescence as described pre-
viously [23]. A comparison was made with the day 0 and
failure day alleles of msp1 and msp2 and the microsatellite
CA1 gene loci.
Possible outcomes were: (i) recrudescence, if the alleles of
the pre- and post-treatment samples were the same for
msp-1, msp-2 and CA1; (ii) re-infection, if the alleles of the
pre- and post-treatment samples are distinct for any one of
these loci; (iii) mixed recrudescence and re-infection, if
similar alleles are found in the pre- and post-treatment
samples for all the markers as mentioned above, but with
additional distinct alleles identified; (iv) indeterminate, if
either or both the pre- and post-treatment samples could
not be amplified. Mixed recrudescent and re-infection
cases were computed as recrudescent.Malaria Journal 2009, 8:63 http://www.malariajournal.com/content/8/1/63
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Outcome measures
The classification of the therapeutic outcome was done
according to the current 28-day WHO protocol [22]. The pri-
mary endpoint was the 28-day cure rates and was defined as
proportion of patients with PCR-corrected adequate clinical
and parasitological response (ACPR) after 28 days of follow-
up. Secondary endpoints were early treatment failure (ETF),
late clinical failure (LCF), late parasitological failure (LPR),
adverse events (clinical and laboratory abnormalities), anae-
mia (haemoglobin value<10 g/dl), clearance rate of fever and
parasitaemia, and gametocyte carriage. Parasite and fever
clearances were assessed on days 1, 2, and 3. The gametocyte
carriage was assessed on days 0, 3, 7, 14, 21, and 28. Adverse
event was defined as a sign, symptom, or abnormal laboratory
value not present on day 0, but which occurred during follow-
up, or was present on day 0 but became worse during follow-
up. Serious adverse events were defined according to ICH
(International Conference on Harmonization) guidelines.
Statistical analysis
The non-inferiority of the AS-SMP 24 hours or AS-SMP 3 days
to AL on the 28-day PCR-corrected cure rates was assessed by
constructing a one-sided, lower limit, asymptotic 97.5% con-
fidence interval (CI) on the difference in cure rates between
AS-SMP 24 hours or AS-SMP 3 days and AL. Non-inferiority
was declared if the lower limit of this CI was greater than -6%
(for AS-SMP 24 hours or AS-SMP three days minus AL). The
non-inferiority margin of 6% was chosen from a cure rate of
94% at day 28 with AL reported in the literature [7]. Likewise,
the non-inferiority of the AS-SMP 24 hours to AS-SMP 3 days
on the 28-day PCR-corrected cure rates by constructing a one-
sided, lower limit, asymptotic 97.5% confidence interval (CI)
on the difference in cure rates between AS-SMP 24 hours and
AS-SMP three days. Non-inferiority was declared if the lower
limit of this CI was greater than -6% (for AS-SMP 24 hours
minus AS-SMP 3 days).
nQuery Advisor 5.0 software was used for sample size calcu-
lation. On the basis of the above assumption, 900 patients
(300 per treatment group) would be needed to demonstrate
non-inferiority stated above with approximately 80% power.
Assuming a 15% non-evaluability rate (e.g. lost to follow-
up) it was planned to enroll 1035, rounded up to 1044 (348
per treatment arm). That total sample size was increased later
to a total of 1,384 subjects included into the study increasing
the precision of the parameters estimate (the efficacy propor-
tion as well as of the secondary objective outcomes such as
adverse events). Data from all sites were pooled and ana-
lyzed based on different populations.
The intent-to-treat (ITT) population analysis included all
randomized subjects. Lost to follow-up and withdrawn
subjects were considered as treatment failure cases.
The per protocol (PP) population analysis included all
subjects who took study medication and made study visits
up to the time of treatment failure or to the end of the
study (28 days). Lost to follow-up and withdrawn subjects
including protocol violation cases were excluded in this
population. The primary analysis was based on the 28-day
PCR corrected efficacy of both ITT and PP populations.
The baseline and safety analysis were done using ITT pop-
ulation. Data were double-entered, validated using Micro-
soft Access and analysed with STATA version 10.0 (STATA
Corporation, TX, USA). Chi-square test with Fisher correc-
tion exact test was used as appropriate to compare categor-
ical variables. Parametric or non-parametric tests were
computed as appropriate to compare continues data
between the three treatments arms. P value less than α =
0.05 was considered as statistically significant.
Ethical clearance
The protocol was reviewed and approved by: the National
Ethical Committee, Yaoundé (for Cameroon),, the Ethical
Committee of the Faculty of Medicine, Pharmacy and
Dentistry at the University of Bamako (for Mali), the
National Ethical Committee, Kigali (for Rwanda), and the
Ethical Review Board of the Academy of Medical Science
and Technology, Faculty of Medicine (for Sudan). Each
patient (or their guardian or parent) gave fully informed
written consent prior the enrollment.
Results
Baseline characteristics
The first patient was enrolled in August 2006 and the
study was completed in May 2007.
Of the 1,384 enrolled participants (Figure 1), 476 were
randomized to receive AS-SMP three days, 458 to receive
AS-SMP 24 hours and 450 to receive AL. Two hundred and
seventy participants were from Cameroon, 261 from Mali,
535 from Rwanda, and 318 from Sudan. Of the 1,384 par-
ticipants, 1,250 completed the study (90.3%), 9.7% were
lost to follow-up or were withdrawn from the study or
from PP analysis (AS-SMP three days, 39/476; AS-SMP 24
hours, 39/458 AL, 56/450). Table 1 shows the baseline
characteristics of all study participants. Demographic and
clinical characteristics at baseline were similar between
treatment groups.
Efficacy
Cure rates on the ITT analysis population were: 96.0% in
the AS-SMP three-day group, 93.7% in the AS-SMP 24-
hour group and 92.0% in the AL group (Table 2). The
lower bound of the one-sided 97.5% CI calculated around
the difference between the day 28 cure rate point esti-
mates in the AS-SMP 24-hour and AS-SMP three-day
groups, AS-SMP 24-hour and AL groups, and AS-SMP
three-day and AL groups were, respectively -2.3%(-5.1,
0.5), 1.7%(-1.7, 5.1) and 4.0%(0.9, 7.1) and thus greater
than the pre-specified -6% non-inferiority limit. Likewise,Malaria Journal 2009, 8:63 http://www.malariajournal.com/content/8/1/63
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The trial profile Figure 1
The trial profile.
N = 1384
Patients enrolled and
randomized
N = 476
AS-SMP 3 days
N = 437
Completed
study
N = 419
Completed
study
N = 394
Completed
study
N = 458
AS-SMP 24 hours
N = 450
AL
N=3 9
Lost/Withdrawn
N=3 9
Lost/Withdrawn
N=5 6
Lost/Withdrawn
Table 1: Baseline characteristics at enrollment
AS-SMP
3 days
(N = 476)
AS-SMP
24 hours
(N = 458)
AL
3 days
(N = 450)
Age (Years)
Median 8.0 9.0 8.0
Min, Max 0.4, 63.5 0.6, 79.0 0.6, 60.0
Age Group (Years)
< 5 – n (%) 153 (32.1) 123 (26.9) 137 (30.4)
Gender
Male – n (%) 239 (50.3) 226 (49.3) 223 (49.6)
P. falciparum (/μl)
Median (IQR) 8400 (3180–24160) 8000 (3200–19520) 7600 (3120–28140)
Gametocyte carriage – n (%) 6 (1.3) 16 (3.5) 8(1.8)
Fever prevalence* – n (%) 332(69.7) 324(70.7) 316(70.2)
N = effective; Std Dev = standard deviation ; IQR = interquartile range
Fever = temperature ≥37.5°C at enrollmentMalaria Journal 2009, 8:63 http://www.malariajournal.com/content/8/1/63
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the cure rates on the PP analysis population were high:
99.3% in the AS-SMP three-day group, 99.5% in the AS-
SMP 24-hour group and 99.7% in the AL group (Table 3).
The lower bound of the one-sided 97.5% CI calculated
around the difference between the day 28 cure rate point
estimates in the AS-SMP 24-hour and AS-SMP three-day
groups, AS-SMP 24 hours and AL groups, and AS-SMP
three-day and AL groups were respectively 0.2%(-0.8,
1.2), -0.2%(-1.1, 0.7) and -0.4%(-1.4, 0.6) and thus
greater than the pre-specified -6% non-inferiority limit.
The PCR uncorrected 28-day cure rates were similar
among treatment groups: 93.7%(446/476) in the AS-SMP
three-day group, 91.1%(417/458) in the AS-SMP 24-hour
group and 89.6%(403/450) in the AL group in the ITT
population. Likewise, the PCR uncorrected 28-day cure
rates were similar among treatment groups: 95.9% (422/
440) in the AS-SMP three-day group, 96.0%(404/421) in
the AS-SMP 24-hour group and 96.0%(380/396) in the
AL group in the PP population. The reinfection rates were
similar among treatment groups: 2.8% in the AS-SMP
three-day group, 3.1% in the AS-SMP 24-hour group and
3.6% in the AL group in the PP population (Table 3).
Overall, there was no discernable difference between
study centers for the primary efficacy variable (Table 4).
There was also no discernable difference in efficacy
between the < 5 years of age group and greater or equal to
5 years of age group (Table 5).
There was a rapid parasite clearance in all treatment
groups (Figure 2): 47.5%(206/434) in the AS-SMP three-
day group, 61.2% (255/417) in the AS-SMP 24-hour
group and 51.8%(203/392) in AL group cleared parasite
on Day 1; p < 0.001. On Day 2, 90.5%(391/432) in the
AS-SMP three-day group, 91.0% (376/413) in the AS-SMP
24-hour group and 90.8%(357/393) in AL group cleared
parasite = 0.96. On Day 3, 99.5%(433/435) in the AS-
SMP three-day group, 99.0% (410/414) in the AS-SMP
24-hour group and 99.2%(388/391) in AL group cleared
parasite = 0.68.
For malaria fever clearance: only 2/405 patients (0.3%)
and 2/387 (0.3%) in the AS-SMP 24-hour group and in
the AL group on day 2 had fever and parasite while the
fever clearance was total in all treatment groups on day 3.
Gametocyte carriage decreased from baseline to day 28. At
baseline on Day 0, 6/432 patients (1.4%) in the AS-SMP
three-day group, 8/394 (2.0%) and 16/418 (3.8%) in the
AS-SMP 24-hour group were carrying gametocytes. Only
2/427 patients (0.5%) in the AS-SMP 3 group, 0/387 (0%)
and 10/410 (2.4%) in the AS-SMP 24-hour group were
carrying gametocytes on day 7; p = 0.001.
There was one patient with ETF in the AL group. Few
patients developed severe malaria: four patients in the AL
group and two in the AS-SMP 24-hour group, all treated
successfully with other anti-malarias treatment (by injec-
tion).
Table 3: Efficacy evaluation on Day 28 after PCR correction* Per-Protocol Analysis
Efficacy evaluation AS-SMP
3 days
(N = 435)
AS-SMP
24 hours
(N = 418)
AL
3 days
(N = 392)
ETF – n (%) 0 0 1(0.3%)
LCF – n (%, 95%CI) 3 (0.7%,0.1–2.0) 2 (0.5%,0.1–1.7) 0
LPF – n (%) 0 0 0
ACPR – n (%, 95%CI) 432 (99.3%,98.0–99.9) 416 (99.5%,98.3–99.9) 391 (99.7%,98.6–100.0)
Reinfection rate – (%, 95%CI) 12 (2.8%,1.4–4.8) 13 (3.1%,1.7–5.3) 14 (3.6%,2.0–5.9)
*Subjects for which filters paper were not analyzed or were undetermined result by PCR or protocol violation cases were excluded
Table 2: Efficacy evaluation on Day 28 after PCR correction* Intention-To-Treat Analysis
Efficacy evaluation AS-SMP
3 days
(N = 476)
AS-SMP
24 hours
(N = 458)
AL
3 days
(N = 450)
Possible failure – n (%, 95%CI) 15(3.2%,1.8–5.1) 26 (5.7%,3.7–8.2) 33(7.3%,5.1–10.1)
ETF – n (%) 0 0 1(0.2%)
LCF – n (%, 95%CI) 3 (0.6%,0.1–1.8) 2 (0.4%,0.1–1.6) 0
LPF – n (%) 0 0 0
ACPR – n (%, 95%CI) 457 (96.0%,93.8–97.6) 429(93.7,91.0–95.7%) 414 (92.0,89.1–94.3%)
*Possible failure: lost to follow-up or withdrawal (a subject** who received high dose of treatment or subjects antibiotics with anti-malarial activity 
or malaria smear results invalidated after quality control) or subjects for which filters paper were not analyzed or were undetermined result by 
PCR
**One subject received on day 0 one dose of a junior tablet of AS-SMP instead of a baby tablet as described in the study procedures and treatment. 
There was no adverse event found to be related to that misuse of the study drug.Malaria Journal 2009, 8:63 http://www.malariajournal.com/content/8/1/63
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Tolerability and safety
The adverse events probably related to study drug were gas-
trointestinal signs/symptoms (vomiting, nausea, diar-
rhoea, abdominal pain, anorexia), dizziness, rash and
weakness. Gastrointestinal signs/symptoms, such as vomit-
ing and diarrhoea, were slightly higher in AS-SMP 24-hour
group: for vomiting, it was 7.0% (n = 458), 4.6% (n = 476)
and 2.2% (n = 450) for AS-SMP 24-hour group, AS-SMP
three-day group and AL group respectively; p = 0.003. For
diarrhoea it was 3.3% (n = 458), 0.6% (n = 476) and 1.3%
(n = 450) for AS-SMP 24-hour group, AS-SMP three-day
group and AL group respectively; p = 0.006 (Table 6). There
was no death reported. There were few serious adverse
events reported (AL, 5/450 [1.1%]; AS-SMP 24 hours, 2/
458 [0.4%]), all being severe malaria except for one severe
case of anaemia in AL group, which occurred a few days
after study drug intake. No clinically significant laboratory
abnormal value (haemogram or liver enzymes, such as ALT
or creatinine or bilirubine) related to study dug has been
reported in any treatment group.
Discussion
Malaria remains a major health problem characterized by
high mortality and serious morbidity in particular with
children less than five years of age [1-3]. Malaria also
impacts on the development of children and later on the
economy of the country [24], so that adequate treatment
compliance may play key role in lowering the malaria bur-
den. With the combination of artesunate-sulphadoxine-
pyrimethamine (AS-SP) it is impossible to make a FDC
tablet, since the total dose of SP must be swallowed at
once on the first day while the artesunate dose is spread
over three days. With other forms of ACT, multiple tablets
may be administered daily over three days [25]. With the
dihydroartemisinin-piperaquine combination, treatment
is over three days and, although an interesting combina-
tion [26], the product suffers from the chemical instability
of DHA (considerable breakdown of DHA when exposed
to higher temperatures) [27,28]. With the AL combina-
tion (Coartem®) problems such as two doses per day over
three days and high re-infection rate in areas with high
transmission intensity are a disadvantage [26]. The
options for the next ten years are limited and, therefore,
new anti-malarials are needed [29].
The current study brings interesting information regard-
ing a new ACT. Previous studies had shown AS-SMP to be
adequate [10-13] and the current study confirmed this on
a larger number of patients from four different geograph-
ical areas of Africa.
Table 5: Efficacy on D28 after PCR correction by age category (Per-Protocol Analysis)
Efficacy evaluation AS-SMP
3 days
AS-SMP
24 hours
AL
3 days
P
Age < 5 years – n 144 111 126
ACPR – n
(%,95%CI)
144
(100%,97.5–100.0)
111
(100%,96.7–100.0)
126
(100%,97.1–100.0)
--
Age >= 5 years – n 293 308 268
ACPR – n
(%,95%CI)
290
(99.0%,97.0–99.8)
306
(99.4%,97.7–99.9)
267
(99.6%,97.9–100.0)
0.78
(Fisher)
*Subjects for which filters paper were not analyzed or were undetermined result by PCR or protocol violation cases were excluded
Table 4: Efficacy on D28 after PCR correction by centre (Per-Protocol Analysis)
Efficacy evaluation AS-SMP
3 days
(N = 435)
AS-SMP
24 hours
(N = 418)
AL
3 days
(N = 392)
Cameroon (n) 85 75 70
ACPR – n (%, 95%CI) 84
(98.8%,93.6–100.0)
74
(98.7,92.8–100.0%)
69
(98.6%,92.3–100.0)
Mali (n) 86 82 85
ACPR – n(%, 95%CI) 86
(100%,95.8–100.0)
82
(100%,95.6–100.0)
85
(100%,95.7–100.0)
Sudan (n) 84 92 73
ACPR – n(%, 95%CI) 84
(100%,95.7–100.0)
92
(100%,96.1–100.0)
73
(100%,95.1–100.0)
Rwanda (n) 180 169 164
ACPR – n(%, 95%CI) 178
(98.9%,96.0–99.9)
168
(99.4%,96.7–100.0)
164
(100%,97.8–100.0)
*Subjects for which filters paper were not analyzed or were undetermined result by PCR or protocol violation cases were excludedMalaria Journal 2009, 8:63 http://www.malariajournal.com/content/8/1/63
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The study shows that the efficacy of the AS-SMP 24-hour
or AS-SMP three-day fixed dose treatment in patients with
acute uncomplicated falciparum malaria was not inferior
to AL, and had a comparable safety profile except for vom-
iting slightly higher in the AS-SMP 24-hour group.
PCR-corrected 28-day cure rates were high in both ITT and
PP analysis in the different treatment groups. The efficacy
rate was comparable across the countries, although the
study was not powered enough for comparing the three
treatment groups within country. Moreover, there was no
difference among the three treatment groups in term of
clearance of fever or parasite (Figure 2), which was rapid
for all treatments. The percentage of excluded patients
(9.7%) was below the pre-specified value of 15%. Results
from ITT and PP analyses were in good agreement.
The PCR-corrected 28-day cure rates in the AS-SMP 24-
hour or AS-SMP three-day group were high and similar to
findings in previously published investigations on the
efficacy of co-blister AS-SMP three-day or fixed AS-SMP
[10-13]. Although similar reinfection rates have been
found in this study (Table 3) a longer period of follow up
would probably have brought out bigger differences in
recurrence rates between treatments.
The AS-SMP was well tolerated in general, particularly the
AS-SMP three-day regimen. No new safety signal was
detected and observations were in line with previous find-
ings [12,13]. Most commonly reported AEs were typical
symptoms of malaria. The most frequently experienced
drug-related AE was vomiting, but this is also typical for
malaria in the first days. Overall, the safety data gathered
in this study did not support any increased risk for AEs
with AS-SMP 24-hour regimen except for vomiting.
This study was performed under supervised study condi-
tions and may, therefore, not entirely mirror normal out-
patient practice, which could be considered as a limitation
of the present trial. To improve the compliance, a fixed
dose of AS-SMP three-day treatment (once daily) or more-
over AS-SMP 24-hour treatment (0–12 h-24 h) has been
developed. This study shows that AS-SMP three-day or AS-
SMP 24 hours is as efficacious as the AL three-day treat-
ment (two doses a day).
In this study, it was clearly demonstrated that the shorten-
ing of the dose interval between tablets from three days to
one day (24 hours) did not compromise the outcome of
the malaria course. However, the second dose of the 12-
hour interval administration drug of AS-SMP and second
dose administration drug of AL may fall outside the regu-
lar working hours of the health centers and also may fall
to patients' bed time and therefore may impact on treat-
ment compliance. In term of efficacy, there was no differ-
ence between treatment groups and the result in each
Table 6: The frequency of adverse events mild to moderate grades from day 1 to day 7 (related or not) after treatment initiation
AS-SMP
3 days (A)
(N = 476)
AS-SMP
24 hours (B)
(N = 458)
AL
3 days (C)
(N = 450)
P-value
Vomiting – n (%) 22 (4.6) 32 (7.0) 10 (2.2) 0.003
Nausea-n (%) 15 (3.2) 19 (4.2) 14 (3.1) 0.6
Headache – n (%) 5 (1.1) 10 (2.2) 7 (1.6) 0.4
Weakness – n (%) 11 (2.3) 5 (1.1) 2 (0.4) 0.04
Anorexia – n (%) 16 (3.4) 11 (2.4) 17 (3.8) 0.5
Dizziness – n (%) 13 (2.7) 14 (3.1) 10 (2.2) 0.7
Diarrhea – n (%) 3 (0.6) 15 (3.3) 6 (1.3) 0.006
Rash – n (%) 3 (0.6) 5 (1.1) 1 (0.2) 0.3
Abdominal pain – n (%) 21 (4.4) 21 (4.6) 17 (3.8) 0.8
Others* – n (%) 15 (3.2) 10 (2.2) 12 (2.7) 0.7
Total – n (%) 124 (26.1) 142 (31.0) 96 (21.3) 0.004
Data are no. (%) of participants with the sign or symptom from day 1 to day 7 after treatment
* Others are: infections (skin, respiratory, intestinal...) pains...
Proportion of participants with parasite during the first 3  days after treatment Figure 2
Proportion of participants with parasite during the 
first 3 days after treatment.
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treatment group approaches 100% in the PP analysis
(ACPR = 99%). This is rather remarkable since the study
was carried out in areas where resistance to SP is high. This
holds for Rwanda where the SP resistance is estimated to
exceed 25% [18]. Also in Cameroun the relative resistance
exceeded 10% [14,15]. In other areas, resistance to SP is
estimated to be ranging from 5% to 30% (Sudan) [19,20].
Recent publications drew attention to the suitability of the
use of ACT in an area where resistance to the partner drug
is high and argued that in areas with high resistance to
pyrimethamine alone or combined with sulphadoxine,
the combination of SP with AS might not be a valid alter-
native therapy [30]. However, in spite of the high SP
resistance in Kigali, Rwanda, the combination with AS
gave a ACPR rate of 90.3% [11]. In the same study, the
combination of AS/SMP (Co-arinate® co-blister) gave a
96.6% ACPR. The high cure rate of AS/SMP compared to
AS/SP in the Rwanda study is also confirmed in this mul-
ticentre study; confirming the chemical activity differ-
ences between SMP and SP [10] even though the
pyrimethamine component is similar for both drugs.
Additional file (additional file 1) has been provided in
order to clarify in more details the difference between sul-
famethoxypyrazine and sulphadoxine. Also the possibil-
ity to combine AS with a drug showing a relative high
resistance, such as SP, was confirmed in a recent study in
Benin and Ghana [31,32]. This should not be considered
as surprising since, in Thailand in the nineties, the combi-
nation of AS with mefloquine gave excellent results in
spite of a high resistance to mefloquine [33]. The study
from Rwanda and Benin using AS+SP are emphasizing
once more that a relatively high resistance to one of the
longer acting partner drugs may not necessarily preclude
it from being used in an ACT.
Conclusion
AS-SMP three days or AS-SMP 24 hours are safe, are as effi-
cacious as AL, and are well tolerated, although vomiting
and diarrhoea were slightly higher in the AS-SMP 24-hour
group than other groups.
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